Literature DB >> 17041466

Macrophage activation syndrome in a patient with systemic onset rheumatoid arthritis: rescue with intravenous immunoglobulin therapy.

Antonio G Tristano1, Lady Casanova-Escalona, Alcira Torres, Martín A Rodríguez.   

Abstract

We report the case of a 7-year-old boy with systemic onset juvenile rheumatoid arthritis (JRA) who developed macrophage activation syndrome during a period of relative remission. He presented with high-grade fever, enlarged lymph nodes, acute hepatitis, severe pancytopenia, and evidence of disseminated intravascular coagulopathy. He became severely ill, with persistent mucosal bleeding, hypovolemia, and vascular instability, and he was admitted to the intensive care unit. No response was observed to treatment with high-dose intravenous corticosteroids and blood product replacements, but the patient fully recovered after the completion of two pulses of intravenous immunoglobulin. This treatment modality may be an alternative to anti-TNF-alpha and cyclosporine A for a prompt response in JRA patients with this potentially fatal condition.

Entities:  

Year:  2003        PMID: 17041466     DOI: 10.1097/01.rhu.0000081259.61370.eb

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  9 in total

Review 1.  Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature.

Authors:  Hafize Emine Sönmez; Selcan Demir; Yelda Bilginer; Seza Özen
Journal:  Clin Rheumatol       Date:  2018-04-16       Impact factor: 2.980

2.  Macrophage activation syndrome in children with systemic onset juvenile idiopathic arthritis: clinical experience from northwest India.

Authors:  Surjit Singh; Shanmuganathan Chandrakasan; Jasmina Ahluwalia; Deepti Suri; Amit Rawat; Nishath Ahmed; Reena Das; M U S Sachdeva; Neelam Varma
Journal:  Rheumatol Int       Date:  2011-01-11       Impact factor: 3.580

Review 3.  Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives.

Authors:  William G Ambler; Kabita Nanda; Karen Brandt Onel; Susan Shenoi
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

Review 4.  Macrophage Activation Syndrome.

Authors:  Ethan S Sen; Sarah L N Clarke; Athimalaipet V Ramanan
Journal:  Indian J Pediatr       Date:  2015-09-24       Impact factor: 1.967

Review 5.  Macrophage activation syndrome and cytokine-directed therapies.

Authors:  Grant S Schulert; Alexei A Grom
Journal:  Best Pract Res Clin Rheumatol       Date:  2014-04       Impact factor: 4.098

6.  Macrophage Activation Syndrome as Onset of Systemic Lupus Erythematosus: A Case Report and a Review of the Literature.

Authors:  Guido Granata; Dario Didona; Giuseppina Stifano; Aldo Feola; Massimo Granata
Journal:  Case Rep Med       Date:  2015-05-07

Review 7.  Rheumatologic emergencies.

Authors:  Luis Arturo Gutiérrez-González
Journal:  Clin Rheumatol       Date:  2015-06-24       Impact factor: 2.980

8.  Macrophage Activation Syndrome, Glomerulonephritis, Pericarditis, and Retinal Vasculitis as Initial Presentation of Systemic Lupus Erythematosus.

Authors:  Yiming Luo; Yumeng Wen; Ana Belen Arevalo Molina; Punya Dahal; Lorenz Leuprecht; Makda Bsrat
Journal:  Case Rep Med       Date:  2018-09-26

9.  Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and γ-immunoglobulin infusions.

Authors:  Sarah Georgiadou; Nikolaos K Gatselis; Aggelos Stefos; Kalliopi Zachou; Konstantinos Makaritsis; Eirini I Rigopoulou; George N Dalekos
Journal:  World J Clin Cases       Date:  2019-11-06       Impact factor: 1.337

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.